Hvivo (HVO) RNS Announcements

Add to Alert list
Date Time Source Announcement
25 Apr 2023 07:00 AM
RNS
Final results
25 Apr 2023 07:00 AM
RNS
Final results
19 Apr 2023 07:10 AM
RNS
Notice of Results
06 Apr 2023 03:54 PM
RNS
Holding(s) in Company
03 Apr 2023 07:00 AM
RNS
Positive results from flu human challenge study
29 Mar 2023 07:00 AM
RNS
Presentation at World Vaccine Congress
23 Mar 2023 07:00 AM
RNS
Exercise of Options
16 Mar 2023 07:00 AM
RNS
Omicron human challenge model update
06 Feb 2023 09:05 AM
RNS
Second Price Monitoring Extn
06 Feb 2023 09:00 AM
RNS
Price Monitoring Extension
06 Feb 2023 07:05 AM
RNS
Long Term Incentive Plan / PDMR Notification
06 Feb 2023 07:00 AM
RNS
£6.8m RSV human challenge contract signed
25 Jan 2023 09:06 AM
RNS
Second Price Monitoring Extn
25 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
25 Jan 2023 07:00 AM
RNS
Trading update
17 Jan 2023 07:00 AM
RNS
EUR3.2m Venn contract with global pharma client
04 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
04 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
04 Jan 2023 07:00 AM
RNS
£5.2m RSV contract and Notice of Trading update
03 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
03 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
03 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
03 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
03 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
03 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
19 Dec 2022 07:00 AM
RNS
Imutex Phase I data published
17 Nov 2022 02:05 PM
RNS
Second Price Monitoring Extn
17 Nov 2022 02:00 PM
RNS
Price Monitoring Extension
14 Nov 2022 11:14 AM
EQS
hVIVO hails growing contract values after winni...
11 Nov 2022 07:00 AM
RNS
Exercise of Options
10 Nov 2022 11:00 AM
RNS
Price Monitoring Extension
10 Nov 2022 08:22 AM
RNS
£13.6m RSV antiviral contract
04 Nov 2022 07:25 AM
RNS
Holding(s) in Company
25 Oct 2022 07:00 AM
RNS
Change of name to hVIVO plc effective
20 Oct 2022 07:00 AM
RNS
Capital Markets Day
18 Oct 2022 07:00 AM
RNS
CFO appointment & change of Board roles
30 Sep 2022 07:00 AM
RNS
Positive in vitro results for FLU-v published
29 Sep 2022 09:30 AM
RNS
Director dealings
27 Sep 2022 07:00 AM
RNS
Upcoming Scientific Presentations
15 Sep 2022 07:00 AM
RNS
Comment regarding press speculation
08 Sep 2022 07:01 AM
RNS
Interim results and trading update
08 Sep 2022 07:00 AM
RNS
Intention to change name to hVIVO plc
01 Sep 2022 07:20 AM
RNS
CAP accreditation
25 Aug 2022 07:00 AM
RNS
Notice of results
22 Aug 2022 07:00 AM
RNS
£10.4m contract with existing Big Pharma client
04 Aug 2022 07:00 AM
RNS
£6.2m Influenza human challenge study contract
05 Jul 2022 01:17 PM
RNS
Result of AGM
30 Jun 2022 07:00 AM
RNS
Omicron human challenge model
14 Jun 2022 07:00 AM
RNS
£7.2m RSV human challenge study contract
10 Jun 2022 12:13 PM
RNS
Board appointment amendment

hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:

hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.

Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.

hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.

hVIVO share price launched at 33p in 2012.

UK 100

Latest directors dealings